BRIEF-Protalix Biotherapeutics announces positive interim results from phase II clinical trial of Alidornase Alfa

* Protalix Biotherapeutics announces positive interim results from phase ii clinical trial of Alidornase Alfa (air dnase) for the treatment of cystic fibrosis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.